Human Amyloid-Beta N3pE-40 ELISA Kit, 2.34- 150 pg/mL Assay Range, Part No. 27418 IBL: kw. ABN3pE-40, beta-amyloid N3pE-40, amyoid beta N3pE-40

Background on Amyloid-Beta N3pE-40

Amyloid-beta (Abeta) is generated through amyloid precursor protein (APP) cleavage by specific secretases.  Beta-secretase cleaves an extracellular portion of APP and frees a soluble peptide. Gamma-secretase cleaves APP within the transmembrane domain, creating amyloid-beta (Aβ) isoforms with lengths between 36-43 amino acid residues.  In N3pE amyloid beta isoforms, the 3rd glutmate residue is converted to pyroglutamate.  N3pE-42 and N3pE-40 variants may have a higher propensity toward aggregation than unmodified amyloid beta, which has been hypothesized to contribute to the Alzheimer's pathology.  This kit selectively detects the N3pE-40 amyloid beta variant, whereas a separate ELISA Kit (Part No. 27716) selectively detects N3pE-42. The affinity purified monoclonal antibody percolated on the ELISA plate and the affiniy purified polyclonal HRP conjugated detection antibody are selective to AβN3pE-40 with minimal cross-reactivity to N3pE-42.. The antibodies have been generated to the N-terminus of AβN3pE-40.

We now also carry a line of ELISA kits with targets that appear to be associated with infection and inflammatory responses that may be associated with dimentia diseases.  For example, alpha-1-proteinase inhibitor (α1-PI), C-reactive protein (CRP), and leukocyte elastase (LE).  To locate this group of ELISA kits, enter the target name in the search bar.

1. Equilibrate plate to RT
   
2. Add sample to plate, incubate overnight
   
3. Add detection antibody, incubate 1 hr
   
4. Add color reagents, 30 min
   
5. Add stop solution.  Measure OD at 450nm
   

 

---

Amyloid-beta N3pE-40 ELISA Kit Validation Data

---

References

1. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci. 1994;17:489-517.
   
2. Wang R, Sweeney D, Gandy SE, Sisodia SS. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem. 1996 Dec 13;271(50):31894-902.
   
3. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron. 1995 Feb;14(2):457-66.
   
4. Horikoshi Y, Mori T, Maeda M, Kinoshita N, Sato K, Yamaguchi H. Abeta N-terminal-end specific antibody reduced beta-amyloid in Alzheimer-model mice. Biochem Biophys Res Co mmun. 2004 Dec 10; 325(2):384-7.
   
5. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun. 2000 Sep 24;276(2):422-7.
   
6. Schilling S, Appl T, Hoffmann T, Cynis H, Schulz K, Jagla W, Friedrich D, Wermann M, Buchholz M, Heiser U, von Hörsten S, Demuth HU. Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ. J Neurochem. 2008 Aug;106(3):1225-36.
   
7. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med. 2008 Oct;14(10):1106-11.

---